KPL-387
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Pericarditis
Conditions
Recurrent Pericarditis, Heart Diseases, Pericarditis
Trial Timeline
Jan 31, 2026 → Dec 31, 2029
NCT ID
NCT07288216About KPL-387
KPL-387 is a phase 2 stage product being developed by Kiniksa Pharmaceuticals for Recurrent Pericarditis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07288216. Target conditions include Recurrent Pericarditis, Heart Diseases, Pericarditis.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Pericarditis were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07288216 | Phase 2 | Recruiting |
Competing Products
20 competing products in Recurrent Pericarditis